Page 2 - கனடியன் காப்புரிமை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Federal Court upholds validity of one pneumococcal vaccine patent, but holds two other patents invalid | Smart & Biggar

Federal Court upholds validity of one pneumococcal vaccine patent, but holds two other patents invalid | Smart & Biggar
jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.

Merckv wyethWhile the courtFederal courtCanadian patentNew drug submissionபோது தி நீதிமன்றம்கூட்டாட்சியின் நீதிமன்றம்கனடியன் காப்புரிமைபுதியது மருந்து சமர்ப்பிப்பு

International Water-Guard Industries Inc (IWG) receives Patents for their Intelligent Pre-Select Water Quantity System

International Water-Guard Industries Inc. (IWG) receives Patents for their Intelligent Pre-Select Water Quantity System Brand Story Canadian Patent No. 2,984,308 and USA Patent No. US 10,815,007 B2 IWG s Intelligent Water Quantity Pre-Select System gives airlines control over the amount of water uploaded into the aircraft by providing real-time data on how much water is used on every flight. By uploading more water than needed, airlines carry and burn more fuel. The typical size of a potable water tank on a commercial narrow-body jet is 60 gallons, which full, weighs approximately 500lbs. The actual water-usage data collected from IWG s Pre-Select System is proving to airlines they can save up to 400lbs per flight by only filling what they need. 400lbs saved every flight can mean millions of dollars in annual fuel savings for large airlines. Furthermore, this System from IWG saves more weight per flight than the combined usual airline weight-saving initiatives such as removing

United statesInternational waterCanadian patentUnited states patentWater quantity pre select systemSelect systemSteven bisIntelligent water quantity pre select systemTransport canadaஒன்றுபட்டது மாநிலங்களில்சர்வதேச தண்ணீர்கனடியன் காப்புரிமைஒன்றுபட்டது மாநிலங்களில் காப்புரிமைதேர்ந்தெடுக்கவும் அமைப்புபுத்திசாலி தண்ணீர் அளவு பிரே தேர்ந்தெடுக்கவும் அமைப்புபோக்குவரத்து கனடா

Federal Court of Appeal finds Minister of Health s refusal to grant a CSP for SHINGRIX is reasonable | Smart & Biggar

To embed, copy and paste the code into your website or blog: In the first appellate decision relating to Certificates of Supplementary Protection (CSPs), the Federal Court of Appeal has allowed the appeal of the Minister of Health (the Minister), setting aside the lower court judgment. In a unanimous decision released on April 14, 2021, the Federal Court of Appeal in Canada (Health) v Glaxosmithkline Biologicals S.A., 2021 FCA 71 found that the Federal Court (see article here) did not correctly apply the applicable standard of review. The Decision Under Review The Minister had found that SHRINGIX contained only one medicinal ingredient a Varicella Zoster Virus (VZV) gE antigen, and that the adjuvant in SHINGRIX was not a medicinal ingredient.

Justice gauthierSupreme courtWhile the federal courtCanada healthv glaxosmithkline biologicalsHealth canadaSupplementary protectionFederal courtVaricella zoster virusCanadian patentPatent actDrug regulationsRegulatory impact analysis statementஉச்ச நீதிமன்றம்போது தி கூட்டாட்சியின் நீதிமன்றம்ஆரோக்கியம் கனடாதுணை ப்ரொடெக்ஶந்

Federal Court upholds Health Canada s strict interpretation of patent listing deadline for KEYTRUDA formulation patent | Smart & Biggar

Merck argued Health Canada unreasonably held that the Time Limits Act) did not have the effect of suspending this 30-day time period. The Time Limits Act suspended a number of federally-legislated deadlines, including time limits related to limitation periods for commencing a court proceeding. Merck argued that subsection 4(6) functions as a “gateway” to the summary litigation provisions of the PMNOC Regulations and therefore the 30-day time period is a “limitation period within a limitation period”. The Federal Court disagreed, holding that the listing of a patent on the Patent Register is too remote from the commencement of a court proceeding: it is not inextricably connected to a prospective civil action, it does not cause time to begin running, there is no precipitating event, there is no defendant at the time of the listing and it is not even the most proximate step to a possible court proceeding.

Procter gamble pharmaceuticals canada incvMerck canada incv healthHealth canadaFederal courtCanadian patentPatent registerMerck canada incPatented medicinesTime limitsTime limits actGamble pharmaceuticals canadaஆரோக்கியம் கனடாகூட்டாட்சியின் நீதிமன்றம்கனடியன் காப்புரிமைகாப்புரிமை பதிவுமெர்க் கனடா இன்க்

Federal Court of Appeal upholds Federal Court decision finding Shire s VYVANSE patent valid

Introduction The Federal Court of Appeal (FCA) recently dismissed Apotex s appeal of the Federal Court decision which held that the claims of Canadian Patent 2,527,646 (the 646 patent) were valid and prohibited the minister of health from issuing a notice of compliance to Apotex for its lisdexamfetamine (LDX) product (Shire s VYVANSE) until the expiry of the 646 patent ( The prohibition application under the pre-amended Patented Medicines (Notice of Compliance) Regulations was consolidated with Apotex s action seeking a declaration of invalidity and non-infringement. Apotex appealed both judgments. Amphetamine was an established treatment for conditions such as attention deficit hyperactivity disorder but as it is an immediate release compound, it requires patients to take doses frequently throughout the day. LDX is a prodrug of amphetamine that provides sustained release and reduces abuse potential.

Apotex incv shireFederal courtCanadian patentApotex incPatented medicinesAustralian patent applicationPatent actAw firmsAw updatesEgal updatesEgal developmentsAw developmentsEgal newslettersEgal current awarenessEgal advisersEgal advisors